anti-LDLR (LDLR) Antikörper

Bezeichnung:
anti-Low Density Lipoprotein Receptor Antikörper (LDLR)
Auf www.antikoerper-online.de finden Sie aktuell 281 Low Density Lipoprotein Receptor (LDLR) Antikörper von 24 unterschiedlichen Herstellern. Zusätzlich bieten wir Ihnen LDLR Kits (50) und LDLR Proteine (39) und viele weitere Produktgruppen zu diesem Protein an. Insgesamt sind aktuell 378 LDLR Produkte verfügbar.
Synonyme:
FH, FHC, Hlb301, LDLA, LDLCQ2, LDLRA

Meistgesuchte Reaktivitäten zu anti-LDLR (LDLR) Antikörper

Wählen Sie die Spezies und Applikation aus

anti-Human LDLR Antikörper:

anti-Mouse (Murine) LDLR Antikörper:

anti-Rat (Rattus) LDLR Antikörper:

Alle verfügbaren anti-LDLR Antikörper

Sie gelangen zu unserer vorgefilterten Suche.

Am meisten referenzierte anti-LDLR Antikörper

  1. Cow (Bovine) Monoclonal LDLR Primary Antibody für ELISA, EM - ABIN4330573 : Jørgensen, Jensen, Holst, Hansen, Corydon, Bross, Bolund, Gregersen: Grp78 is involved in retention of mutant low density lipoprotein receptor protein in the endoplasmic reticulum. in The Journal of biological chemistry 2000 (PubMed)
    Zeige alle 16 Referenzen für 4330573

  2. Cow (Bovine) Polyclonal LDLR Primary Antibody für WB - ABIN223504 : Dong, Wu, Li, Kraemer, Adeli, Seidah, Park, Liu: Strong induction of PCSK9 gene expression through HNF1{alpha} and SREBP2: Mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters. in Journal of lipid research 2010 (PubMed)
    Zeige alle 7 Referenzen für 223504

  3. Human Polyclonal LDLR Primary Antibody für IF (p), IHC (p) - ABIN672111 : Wu, He, Wang, Xue, Ning, Zou, Ye, Li, Wang, Pang: The antihypercholesterolemic effect of jatrorrhizine isolated from Rhizoma Coptidis. in Phytomedicine : international journal of phytotherapy and phytopharmacology 2014 (PubMed)
    Zeige alle 4 Referenzen für 672111

  4. Human Monoclonal LDLR Primary Antibody für ELISA (Capture), FACS - ABIN4899696 : Boucrot, Ferreira, Almeida-Souza, Debard, Vallis, Howard, Bertot, Sauvonnet, McMahon: Endophilin marks and controls a clathrin-independent endocytic pathway. in Nature 2015 (PubMed)
    Zeige alle 3 Referenzen für 4899696

  5. Human Polyclonal LDLR Primary Antibody für ICC, IF - ABIN438622 : Wang, Gao, Liao, Qi, Du, Wang, Li, Liu, Yang: Adipose tissue deficiency results in severe hyperlipidemia and atherosclerosis in the low-density lipoprotein receptor knockout mice. in Biochimica et biophysica acta 2016 (PubMed)
    Zeige alle 3 Referenzen für 438622

  6. Human Monoclonal LDLR Primary Antibody für FACS - ABIN4896539 : Le, Blanchet, Seidah, Labonté: Plasma Membrane Tetraspanin CD81 Complexes with Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) and Low Density Lipoprotein Receptor (LDLR), and Its Levels Are Reduced by PCSK9. in The Journal of biological chemistry 2015 (PubMed)
    Zeige alle 3 Referenzen für 4896539

  7. Human Monoclonal LDLR Primary Antibody für FACS - ABIN4896543 : Ramanathan, Gusarova, Stahl, Gurnett-Bander, Kyratsous: Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes. in PLoS ONE 2016 (PubMed)
    Zeige alle 3 Referenzen für 4896543

  8. Mouse (Murine) Polyclonal LDLR Primary Antibody für FACS, ICC - ABIN4899698 : Seidah, Poirier, Denis, Parker, Miao, Mapelli, Prat, Wassef, Davignon, Hajjar, Mayer: Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation. in PLoS ONE 2012 (PubMed)

  9. Human Polyclonal LDLR Primary Antibody für FACS, WB - ABIN652907 : Brown, Goldstein: Receptor-mediated endocytosis: insights from the lipoprotein receptor system. in Proceedings of the National Academy of Sciences of the United States of America 1979 (PubMed)

  10. Mouse (Murine) Monoclonal LDLR Primary Antibody für FACS, WB - ABIN4899699 : Rousselet, Marcinkiewicz, Kriz, Zhou, Hatten, Prat, Seidah: PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke. in Journal of lipid research 2011 (PubMed)

Weitere Antikörper gegen LDLR Interaktionspartner

Human Low Density Lipoprotein Receptor (LDLR) Interaktionspartner

  1. PCSK9 (zeige PCSK9 Antikörper) inhibits lipoprotein(a) clearance through the LDLR.

  2. 4 siblings found to be compound heterozygotes for 2 LDLR gene mutations but showing a different phenotype severity

  3. LDLR is a relevant receptor for CNS drug delivery via receptor-mediated transcytosis and that the peptide vectors we developed have the potential to transport drugs

  4. Higher Gleason grade was associated with lower LDLR expression, lower SOAT1 (zeige SOAT1 Antikörper) and higher SQLE (zeige SQLE Antikörper) expression. Besides high SQLE (zeige SQLE Antikörper) expression, cancers that became lethal despite primary treatment were characterized by low LDLR expression (odds ratio for highest versus lowest quintile, 0.37; 95% CI 0.18-0.76) and by low SOAT1 (zeige SOAT1 Antikörper) expression (odds ratio, 0.41; 95% CI 0.21-0.83).

  5. LDLR associated with Familial Hypercholesterolemia and Polygenic Hypercholesterolemia in patients with Acute Coronary Syndrome , age /=160 mg/dl.

  6. Chinese W483X mutation in the low-density lipoprotein-receptor gene in young patients with homozygous familial hypercholesterolemia

  7. Proprotein convertase subtilisin (zeige PCSK9 Antikörper)/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia

  8. both LDLR rs6511720 and rs57217136 are functional variants; both these minor alleles create enhancer-binding protein sites for transcription factors and may contribute to increased LDLR expression, which is consequently associated with reduced LDL-C levels and 12% lower coronary heart disease risk

  9. Using assays that measured conformational change, acid-dependent lipoprotein release, LDLR recycling, and net lipoprotein uptake, we show that H635 plays important roles in acid-dependent conformational change and lipoprotein release, while H264, H306, and H439 play ancillary roles in the response of the LDLR to acidic pH

  10. these studies support that reductions in Lp(a (zeige APOA Antikörper)) with PCSK9 (zeige PCSK9 Antikörper) inhibition are partly due to increased LDLR-mediated uptake. In most situations, Lp(a (zeige APOA Antikörper)) appears to compete poorly with LDL for LDLR binding and internalization, but when LDLR expression is increased with evolocumab, particularly in the setting of low circulating LDL, Lp(a (zeige APOA Antikörper)) is reduced.

Cow (Bovine) Low Density Lipoprotein Receptor (LDLR) Interaktionspartner

  1. Nonesterified fatty acids significantly inhibit the expression of ApoB100 (zeige APOB Antikörper), ApoE (zeige APOE Antikörper), MTP (zeige MTTP Antikörper), and LDLR, thereby decreasing the synthesis and assembly of VLDL and inducing TG accumulation in bovine hepatocytes.

Mouse (Murine) Low Density Lipoprotein Receptor (LDLR) Interaktionspartner

  1. PCSK9 (zeige PCSK9 Antikörper) inhibits lipoprotein(a) clearance through the LDLR.

  2. PTP1B (zeige PTPN1 Antikörper) inhibitors protect against atherosclerotic plaque formation in the LDLR(-/-) mouse model of atherosclerosis.

  3. LDLR is a relevant receptor for CNS drug delivery via receptor-mediated transcytosis and that the peptide vectors we developed have the potential to transport drugs

  4. ApoC-III (zeige APOC3 Antikörper) inhibits turnover of TG-rich lipoproteins primarily through a hepatic clearance mechanism mediated by the LDLR/LRP1 (zeige LRP1 Antikörper) axis

  5. Leukocyte GPR120/FFAR4 (zeige O3FAR1 Antikörper) WT or KO mice in the LDL receptor KO background were generated by bone marrow transplantation.leukocyte GPR120 (zeige O3FAR1 Antikörper) expression has minimal effects on dietary PUFA-induced plasma lipid/lipoprotein reduction and atheroprotection, and there is no distinction between n-3 versus n-6 PUFAs in activating anti-inflammatory effects of leukocyte GPR120/FFAR4 (zeige O3FAR1 Antikörper) in vivo

  6. This study reports the creation of a mouse model of autoimmunity-associated atherosclerosis by transplanting bone marrow from FcgammaRIIB knockout (FcRIIB(-/-)) mice into LDL receptor knockout mice.

  7. hepatocytes clear lipopolysaccharides from the circulation via the LDLR.

  8. Atherosclerosis and Hypercholesterolemia in Mice Lacking Both the Melanocortin Type 4 Receptor and Low Density Lipoprotein Receptor

  9. Cyclosporin A does not cause hyperlipidemia via direct effects on the LDLr. Rather, LDLr deficiency plays an important permissive role for CsA (zeige HSPA9 Antikörper)-induced hyperlipidemia, which is associated with abnormal lipoprotein clearance, decreased lipoprotein lipase (zeige LPL Antikörper) activity, and increased levels of apolipoprotein C-III (zeige APOC3 Antikörper) and proprotein convertase subtilisin/kexin type 9 (zeige PCSK9 Antikörper).

  10. Ldlr(-/-) Creb3l3 (zeige CREB3L3 Antikörper)(-/-) mice developed significantly more atherosclerotic lesions in the aortas than Ldlr(-/-) mice.

Pig (Porcine) Low Density Lipoprotein Receptor (LDLR) Interaktionspartner

  1. The LDLR gene should be a candidate causative gene for LDL-cholesterol and total cholesterol in pigs, but heterogeneity exists in different populations.

  2. KLF13 (zeige KLF13 Antikörper) and SREBP-Sp1 (zeige SP1 Antikörper) activation interact to regulate low density lipoprotein receptor promoter function

  3. found association between genotypes for LDLR and APOB (zeige APOB Antikörper) polymorphisms and serum lipid levels, but none of them seem to be the causal mutation but probably represent closely linked polymorphisms

LDLR Antigen-Profil

Beschreibung des Gens

The low density lipoprotein receptor (LDLR) gene family consists of cell surface proteins involved in receptor-mediated endocytosis of specific ligands. Low density lipoprotein (LDL) is normally bound at the cell membrane and taken into the cell ending up in lysosomes where the protein is degraded and the cholesterol is made available for repression of microsomal enzyme 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, the rate-limiting step in cholesterol synthesis. At the same time, a reciprocal stimulation of cholesterol ester synthesis takes place. Mutations in this gene cause the autosomal dominant disorder, familial hypercholesterolemia. Alternate splicing results in multiple transcript variants.

Alternative names and synonyms associated with LDLR

  • low density lipoprotein receptor (ldlr) Antikörper
  • low density lipoprotein receptor (LDLR) Antikörper
  • low density lipoprotein receptor (Ldlr) Antikörper
  • low density protein receptor (LOC443535) Antikörper
  • FH Antikörper
  • FHC Antikörper
  • Hlb301 Antikörper
  • LDLA Antikörper
  • LDLCQ2 Antikörper
  • LDLRA Antikörper

Bezeichner auf Proteinebene für LDLR

low-density lipoprotein receptor , LDL receptor , low-density lipoprotein receptor class A domain-containing protein 3 , low density lipoprotein receptor (familial hypercholesterolemia)

GENE ID SPEZIES
387529 Danio rerio
3949 Homo sapiens
281276 Bos taurus
100009086 Oryctolagus cuniculus
16835 Mus musculus
300438 Rattus norvegicus
100724238 Cavia porcellus
396801 Sus scrofa
100683160 Canis lupus familiaris
395103 Gallus gallus
100689399 Cricetulus griseus
443535 Ovis aries
Ausgewählte Anbieter für anti-LDLR (LDLR) Antikörper
Haben Sie etwas anderes gesucht?